To develop and commercialize early-to-mid-stage psychiatry pipeline including assets for for schizophrenia, treatment-resistant depression and anhedonia.
VelociSuite technologies facilitate rapid generation of optimized antibodies allowing for cell line production and large-scale bioreactor manufacturing